Holen Sie sich die Stockscreener-App
65.10
1.56%
1.00
Vorhandelsmarkt:
65.40
0.30
+0.46%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$64.10
Offen:
$65.03
24-Stunden-Volumen:
1.85M
Relative Volume:
0.62
Marktkapitalisierung:
$9.12B
Einnahmen:
$1.09B
Nettoeinkommen (Verlust:
$233.57M
KGV:
42.32
EPS:
1.5382
Netto-Cashflow:
$327.01M
1W Leistung:
+5.66%
1M Leistung:
-4.35%
6M Leistung:
+132.50%
1J Leistung:
+280.48%
1-Tages-Spanne:
$62.96
$66.05
1-Wochen-Bereich:
$60.88
$67.15
52-Wochen-Spanne:
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
65.10 | 8.98B | 1.09B | 233.57M | 327.01M | 1.5382 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference - Yahoo Finance
Rafferty Asset Management LLC Sells 27,546 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Fisher Asset Management LLC Acquires 602,139 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals at TD Cowen Conference: Strategic Insights in Cardiometabolic Focus - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. (ARWR) Competitors - Meyka
ARWR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation As Its RNAi Pipeline Advances To Phase 3 With Big Pharma Partners - simplywall.st
Erste Asset Management GmbH Has $2.47 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Position Increased by JPMorgan Chase & Co. - MarketBeat
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns - Yahoo Finance
Arrowhead’s Expanded 2026 Conference Circuit and Phase 3 RNAi Pipeline Might Change The Case For Investing In Arrowhead Pharmaceuticals (ARWR) - Sahm
Vanguard Group Inc. Has $553.08 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Net current asset value per share of Arrowhead Pharmaceuticals, Inc. – DUS:HDP1 - TradingView
Arrowhead Pharmaceuticals Achieves 201.24% Return, Establishing It as a Multibagger in Biotechnology - Markets Mojo
Arrowhead Pharmaceuticals, Inc. (ARWR): An Investor Outlook on Its 28.86% Potential Upside - DirectorsTalk Interviews
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events - Business Wire
Responsive Playbooks and the ARWR Inflection - Stock Traders Daily
Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by King Luther Capital Management Corp - MarketBeat
Reviewing Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Nutra Pharma (OTCMKTS:NPHC) - Defense World
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity - ChartMill
Rhumbline Advisers Buys 11,115 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - Defense World
Aberdeen Group plc Sells 439,601 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited - Finviz
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely Limited - Yahoo Finance
Strategic Shift in Biopharma Dealmaking - Intellectia AI
Fundamentals Check: Can Arrowhead Pharmaceuticals Inc weather a recessionEarnings Growth Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Arrowhead Pharmaceuticals (ARWR) Investor Outlook: Exploring the 27.49% Upside Potential - DirectorsTalk Interviews
Piper Sandler highlights Arrowhead Pharmaceuticals, Inc. (ARWR) pipeline with upcoming phase III hypertriglyceridemia data - MSN
Public Sector Pension Investment Board Grows Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
AlphaQuest LLC Sells 30,501 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Arrowhead Pharmaceuticals Inc. stock benefit from automationJuly 2025 Review & Weekly Chart Analysis and Trade Guides - mfd.ru
What’s the beta of Arrowhead Pharmaceuticals Inc. stockWeekly Trade Recap & Accurate Entry and Exit Point Alerts - mfd.ru
What are Arrowhead Pharmaceuticals Inc.’s recent SEC filings showingProfit Target & Capital Protection Trading Alerts - mfd.ru
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
Is Arrowhead Pharmaceuticals Inc. gaining market shareTrade Risk Assessment & Verified Momentum Stock Watchlist - mfd.ru
Zacks Research Issues Negative Estimate for ARWR Earnings - MarketBeat
Johnson Investment Counsel Inc. Makes New $781,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Equities Analysts Issue Forecasts for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality - simplywall.st
The Strong Earnings Posted By Arrowhead Pharmaceuticals (NASDAQ:ARWR) Are A Good Indication Of The Strength Of The Business - 富途牛牛
Understanding the Setup: (ARWR) and Scalable Risk - Stock Traders Daily
ARWR: Strong Start for REDEMPLO Commercialization - Smartkarma
ARWR: Strong Start for REDEMPLO Commercialization… - Yahoo Finance
Arrowhead Joins S&P 400 As Profitability Shifts Investor Focus - Sahm
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Arrowhead Pharma (ARWR) Receives Buy Rating from HC Wainwright | - GuruFocus
Breaking Down Arrowhead Pharma: 18 Analysts Share Their Views - Benzinga
Goldman Sachs Maintains Neutral on ARWR Arrowhead Pharmaceuticals Feb 2026 - Meyka
Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR) - TechStock²
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):